Clinical Trials Browser

Bevacizumab × CNS × 90 days × Clear all

NCT02971501 2026-03-17

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

Phase 2 Active not recruiting

7 enrolled 9 charts

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07297212 2026-03-12

A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma

Phase 2 Recruiting

Brain Neoplasms, Glioblastoma

NCT07449481 2026-03-04

A Single-Arm, Open-Label, Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors

Phase 2 Not yet recruiting

Brain Neoplasms

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Phase 1/2 Recruiting

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT06663306 2026-03-02

Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Carcinomatosis

NCT06888817 2026-02-25

BRAINS

Phase 3 Recruiting

Brain Neoplasms, Glioma, Radiation Injuries

NCT01356290 2026-02-23

MEMMAT

Phase 2 Recruiting

Ependymoma, Medulloblastoma, Recurrence

NCT02669173 2026-02-23

Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma

Phase 1 Completed

Brain Neoplasms, Glioblastoma, Recurrence

NCT06955169 2026-02-17

MOMENTUM-1

Phase 2 Recruiting

Meningioma

NCT07263438 2026-02-13

Phenix

Phase 2 Recruiting

Glioblastoma, Recurrence

NCT06061809 2026-02-12

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

Phase 2 Recruiting

Glioblastoma

NCT04743661 2026-02-05

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Phase 2 Active not recruiting

Ependymoma, Medulloblastoma

NCT07346157 2026-01-16

PNOC044

Phase 1/2 Not yet recruiting

Medulloblastoma

NCT05871021 2026-01-09

PRIDE

Phase 2 Recruiting

Glioblastoma

NCT02698254 2026-01-07

Radiation Therapy in Treating Patients With Recurrent Brain Tumors Who Have Undergone Previous Radiation Therapy

Phase NA Active not recruiting

Brain Neoplasms

NCT03743662 2026-01-07

Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma

Phase 2 Active not recruiting

Glioblastoma